MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
39.97
+1.50 (3.90%)
May 12, 2025, 10:05 AM - Market open
MLTX Analyst Ratings
Total Analysts
8
Consensus Rating
Strong Buy
Price Target
$80.50
Upside
+101.40%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +65.12% | Apr 30, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $67 | Buy | Initiates | $67 | +67.63% | Mar 18, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $82 → $73 | Strong Buy | Maintains | $82 → $73 | +82.64% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +150.19% | Feb 27, 2025 |
| Needham | Needham | Strong Buy Maintains $62 → $66 | Strong Buy | Maintains | $62 → $66 | +65.12% | Feb 27, 2025 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $62 → $82 | Hold → Strong Buy | Upgrades | $62 → $82 | +105.15% | Jan 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +150.19% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +150.19% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +150.19% | Nov 8, 2024 |
| Wedbush | Wedbush | Buy Initiates $92 → $73 | Buy | Initiates | $92 → $73 | +82.64% | Nov 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +150.19% | Oct 15, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +150.19% | Sep 12, 2024 |
| Needham | Needham | Strong Buy Reiterates $62 | Strong Buy | Reiterates | $62 | +55.12% | Sep 12, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 9, 2024 |
| Wolfe Research | Wolfe Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Aug 26, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.